Project Description

At First

Pharmaceutical firms doing genetic research reach out to people with the necessary genetic material and sensitively discuss the aims of the research, but they do not necessarily discuss benefits. Should they?

Our Solution

Involve disease group communities and genetic material founder populations on the meaning of “benefits” and have similar conversations with pharmaceutical firms and researches to see if there is common ground.

The Result

A benefit sharing document was co-created that could be given to all participants of genetic research, outlining the possibilities of benefit sharing agreements.